Enliven Therapeutics(US:ELVN) ZACKS·2025-12-03 15:55Core Viewpoint - Enliven Therapeutics, Inc. (ELVN) has seen an 8.2% increase in share price over the past four weeks, closing at $20.56, with a potential upside of 101.3% based on Wall Street analysts' mean price target of $41.38 [1][12]. Price Targets - The average price target consists of eight estimates ranging from a low of $33.00 to a high of $52.00, with a standard deviation of $6.52, indicating a potential increase of 60.5% to 152.9% from the current price [2][9]. - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [2][9]. Analyst Sentiment - Analysts are optimistic about ELVN's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a strong correlation with near-term stock price movements [4][11]. - The Zacks Consensus Estimate for the current year has increased by 9% over the past month, with two estimates revised upward and no negative revisions [12]. Zacks Rank - ELVN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, which further supports the stock's potential upside [13]. Conclusion on Price Targets - While the consensus price target may not be a reliable indicator of the extent of ELVN's potential gains, it does provide a useful guide for the direction of price movement [14].